Qingdao Luye SCO Pharmaceutical Technology Co., Ltd.

Luye Pharma Group (02186.HK), is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. Its core therapeutic areas include central nervous system (CNS), oncology, and cardiovascular diseases.The group has R&D centers in China and Europe.The group has 8 manufacturing sites built following ICH guidelines from product design to facility construction.It conducts business in over 80 countries and regions around the world, including major pharmaceutical markets such as China, theU.S., Europe, and Japan, as well as fast-growing emerging markets.From 2021 to 2025, it had a total of 15 new drugs approved for marketing.